{
  "abstract": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cardiology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan",
    "Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, Yufu, Oita, Japan",
    "Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan"
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Naoyuki Otani",
      "orcid": "0000-0002-0127-2118"
    },
    {
      "affs": [
        2
      ],
      "name": "Takushi Sugiyama"
    },
    {
      "affs": [
        2
      ],
      "name": "Yasuhiro Maejima"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5hfzak8y6zb0q.bib",
  "cited_by": 0,
  "doi": "10.1136/bcr-2026-275554",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13755897/",
  "id": "5hfzak8y6zb0q",
  "issns": [
    "1757-790X"
  ],
  "landing_url": "https://doi.org/10.1136/bcr-2026-275554",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Case Report"
    ],
    [
      "heading",
      "Clinical Pharmacology"
    ],
    [
      "openalex",
      "2727|Gout, Hyperuricemia, Uric Acid"
    ]
  ],
  "openalex": "W7225340195",
  "pdf_url": "https://casereports.bmj.com/content/bmjcr/19/11/e275554.full.pdf",
  "pmcid": "PMC13755897",
  "pmid": "42988439",
  "published": "2026-11-05",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/5hfzak8y6zb0q.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:21:53Z",
      "native_id": "PMC13755897",
      "source": "pmc",
      "url": "https://doi.org/10.1136/bcr-2026-275554"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2727|Gout, Hyperuricemia, Uric Acid",
      "subfield": "general"
    }
  ],
  "title": "Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure",
  "title_text": "Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:21:53Z",
  "url": "https://research.draconitic.com/paper/5hfzak8y6zb0q",
  "venue": "BMJ Case Reports",
  "versions": []
}